Staff
Between 2011 and 2024, 82% of the full-time equivalents disappeared.
Between 2011 and 2024, 82% of the full-time equivalents disappeared.
LINVATEC BELGIUM pays its suppliers 48 days earlier than in 2023.
Short-term debts fell from €556,597 to €458,960.
2025 accounts not filed: deadline was 31-07-2026.
Board changed. Latest change 30-10-2026 · 3 in office.
Higher solvency than 95% of companies in wholesale trade. Sector median 42.0% · 6,060 companies.
The dashed line is the sector median: 0.4% across 26,892 companies (NACE 46, micro).
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro). It does better than 90% of them on solvency, 53% on liquidity, 24% on profitability and 41% on growth.
The bankruptcy probability was computed on 07-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2024.
Of the companies with a bankruptcy probability in the moderate class on 30-06-2025, 2.4% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Liquidity is ample, with a current ratio of 14.16 (1.14 in 2023), above the usual 1.5. Short-term debt is 0.3% and cash 0.2% of total assets. 0.3% of the assets are financed with debt and provisions.
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
The company filed its last 6 accounts on average 369 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Shares in 1 company, CONMED Europe
Board & ownership| Company | ||||
|---|---|---|---|---|
| LINVATEC BELGIUM Drogenbos | - | - | 99.7% | 1.9 |
| OMRIX BIOPHARMACEUTICALS Machelen (Brab.) | €107.0m | -1.4% | 27.7% | 1 |
| BESINS HEALTHCARE Ixelles | €11.1m | 9.2% | 89.6% | 4.9 |
| KANEKA MEDICAL EUROPE Zaventem | €58.0m | 8.1% | 62.9% | 7 |
| Mirion Technologies (Canberra BNLS) Asse | €8.8m | 19.1% | 29.3% | 11.7 |
| PORTON EUROPE Turnhout | €64.7m | 1.9% | 43.1% | 1 |
| Nipro PharmaPackaging International Mechelen | €2.2m | -8.7% | 52.8% | 5 |
These companies have the same main activity as LINVATEC BELGIUM: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €31m and €362m, founded between 1988 and 2015.
LINVATEC BELGIUM has existed since 2000. Turnover fell from €3.0m in 2013 to €807,280 in 2014 and staff from 10.6 to 1 full-time equivalents.
Linvatec Nederland holds all the shares. In January 2026, the Official Gazette published the appointment of Sven Van Kets as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
See how customers, suppliers and banks see your own company and what to improve first.
If something looks wrong or is missing, please tell us.